Philo International Launches New IQOS ILUMA E-Cigarettes in Korea

Oct.25.2022
Philo International Launches New IQOS ILUMA E-Cigarettes in Korea
Fimo International's new generation e-cigarette device sparks competition in the Korean market. IQOS ILUMA aims to regain market share.

Phimo International's South Korean subsidiary has reignited competition in the domestic electronic cigarette market with the release of their next generation electronic cigarette device. With the launch of this new product, Phimo International's South Korean subsidiary hopes to reclaim the top spot in the Korean market, once again competing with KT&G for the highest market share.


On the morning of the 25th, Philip Morris International's Korean company held a press conference at Lotte Hotel in Sogong-dong, Seoul to announce the official launch of their new product series, "IQOS ILUMA," in South Korea.


Yachek Olzac, CEO of Philip Morris' international South Korean company, stated, "By expanding its product portfolio through the release of multiple generations of IQOS, Philip Morris continues to innovate and pursue its vision of a smoke-free future. The launch of the IQOS Illuma series offers adult smokers a better choice and a game-changing opportunity to accelerate their transition from conventional smoking," he said.


With the release of new products, the focus is on whether Philip Morris Korea will regain its position as the leader in the domestic electronic cigarette market. Since the launch of IQOS in 2017, Philip Morris Korea has maintained its leading position in the domestic electronic cigarette market for about five years. However, in the first quarter of this year, KT&G's release of "Reel Solid 2.0" resulted in their taking the top market share position, with the gap widening in the second quarter. Just as Philip Morris Korea is set to launch new products to shake up the market, KT&G also plans to release new products on September 9 to solidify their position. Therefore, competition in the electronic cigarette market is expected to intensify by the end of the year.


Statement:


This article is compiled based on third-party information and is intended solely for industry professionals to exchange and learn from.


This article does not represent the views of 2FIRSTS, and 2FIRSTS is unable to confirm the authenticity and accuracy of the article's content. The compilation of this article is solely for industry-related communication and research.


Due to limitations in the translator's skills, the translated article may not fully convey the intended meaning of the original text. Therefore, the original text should be considered the primary source.


2FIRSTS maintains a consistent stance with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, and foreign-related matters.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

FDA Commissioner Stresses “Predictability” as Science Chief Addresses Industry Uncertainty
FDA Commissioner Stresses “Predictability” as Science Chief Addresses Industry Uncertainty
FDA Commissioner Marty Makary briefly appeared at the February 10 PMTA roundtable, underscoring the importance of regulatory predictability. At the close of the session, Office of Science Director Matthew Farrelly responded to industry concerns over review uncertainty, stating the agency will issue a written summary of feedback, while reiterating that no fixed quantitative risk benchmark governs authorization decisions.
Feb.11
PMI Flags 2026 Headwinds from Japan Taxes, Sees Smoke-Free Growth Re-Accelerating Beyond in Earnings Call
PMI Flags 2026 Headwinds from Japan Taxes, Sees Smoke-Free Growth Re-Accelerating Beyond in Earnings Call
PMI said on its latest earnings call that Japan’s tax cycle will weigh on 2026 performance, while smoke-free growth is expected to re-accelerate thereafter. The discussion also covered U.S. regulation, ZYN strategy and AI-driven efficiency.
Feb.07
BAT says a U.S. import block on some disposable vapes could cut illegal sales by about a third
BAT says a U.S. import block on some disposable vapes could cut illegal sales by about a third
Reuters reported that British American Tobacco (BAT) CEO Tadeu Marroco said a potential U.S. move to block imports of some disposable vapes could reduce the market for unregulated e-cigarettes by as much as a third, though any impact is unlikely before 2027.
Feb.13 by 2FIRSTS.ai
2Firsts Observation | Element Vape Launches “Made in USA” Section as Product Pages Show “Assembled in USA” and “Made in USA” Labels
2Firsts Observation | Element Vape Launches “Made in USA” Section as Product Pages Show “Assembled in USA” and “Made in USA” Labels
Element Vape, a U.S. online vaping retailer, uses origin labels such as “Made in USA” and “Assembled in USA” across disposable vape product pages and a dedicated collection page, grouping items under “Made in USA Disposable Vapes,” but the platform does not disclose on its public pages the applicable standards or evidentiary basis for these different claims.
Jan.20 by 2FIRSTS.ai
BREAKING: China Brings Nicotine Pouches Under Tobacco Monopoly Regulation, Signaling Major Shift for Oral Products
BREAKING: China Brings Nicotine Pouches Under Tobacco Monopoly Regulation, Signaling Major Shift for Oral Products
China has for the first time issued clear regulatory rules for nicotine pouches and other oral nicotine products, formally classifying them under the tobacco monopoly alongside cigarettes and tobacco, ending a long-standing legal grey zone and laying the regulatory groundwork for their potential domestic launch.
Jan.09 by Alan Zhao | 2Firsts Perspectives
BAT Malaysia names Mohd Nizom Sairi as board chairman effective January 1, 2026
BAT Malaysia names Mohd Nizom Sairi as board chairman effective January 1, 2026
BAT Malaysia announced that its independent non-executive director Datuk Seri Dr Mohd Nizom Sairi has been re-designated as board chairman effective January 1, 2026.
Jan.04 by 2FIRSTS.ai